HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study.

Abstract
Human epidermal growth factor receptor (HER1) constitutes a tumor associated antigen. Its overexpression in many epithelial tumors has been associated with bad prognosis and poor survival. Cancer vaccine based on the extracellular domain (ECD) of HER1 and adjuvated in very small sized proteoliposomes (VSSP) and Montanide ISA 51-VG is a new and complementary approach for the treatment of epithelial tumors. The present study deals with the immunogenicity of this vaccine in Macaca fascicularis monkeys and evaluation of its toxicity during 12 months. Twelve monkeys were randomized into two groups of 3 animals per sex: control and vaccinated. Treated monkeys received 9 doses of vaccination and were daily inspected for clinical signs. Body weight, rectal temperature, cardiac and respiratory rates were measured during the study. Humoral immune response, clinical pathology parameters and delayed type hypensensitivity were analyzed. Skin biopsy was performed at the end of the study in all animals. Animal's survival in the study was 100% (n=12). Local reactions were observed at the administration site of four treated animals (n=6), with two showing slight inflammatory cutaneous damage. Clinical pathology parameters were not affected. HER1 vaccine induced high IgG antibodies titers in the treated animals even when DTH was not observed. The induced antibodies recognized HER1+ tumor cell lines, decreased HER1 phosphorylation and showed anti-proliferative and pro-apoptotic effects in H125 cells. In general the present study showed that HER1 vaccine induced specific immune response in M. fascicularis monkeys and was well tolerated, suggesting it could be safely used in clinical studies in epithelial cancer patients.
AuthorsAna M Bada Barro, Arianna Iglesias Rivero, Avelina León Goñi, Bárbara O González Navarro, Meilis Mesa Angarica, Belinda Sánchez Ramírez, Darel Martínez Bedoya, Consuelo González Triana, Axel Mancebo Rodríguez, Ángel Casacó Parada
JournalVaccine (Vaccine) Vol. 31 Issue 1 Pg. 89-95 (Dec 17 2012) ISSN: 1873-2518 [Electronic] Netherlands
PMID23142132 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies
  • Cancer Vaccines
  • EGFR protein, human
  • ErbB Receptors
Topics
  • Animals
  • Antibodies
  • Blotting, Western
  • Body Weight (physiology)
  • Cancer Vaccines (administration & dosage, immunology, therapeutic use)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • ErbB Receptors (immunology)
  • Female
  • Flow Cytometry
  • Humans
  • Immunoenzyme Techniques
  • Macaca fascicularis (immunology)
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: